Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Vanda Pharmaceuticals (VNDA) Other Gross PP&E Adjustments (2016 - 2025)

Vanda Pharmaceuticals' Other Gross PP&E Adjustments history spans 15 years, with the latest figure at $7.5 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments fell 14.1% to $7.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.5 million, a 14.1% decrease, with the full-year FY2025 number at $7.5 million, down 14.1% from a year prior.
  • Other Gross PP&E Adjustments hit $7.5 million in Q4 2025 for Vanda Pharmaceuticals, up from -$6.1 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for VNDA hit a ceiling of $8.8 million in Q4 2024 and a floor of -$12.0 million in Q1 2024.
  • Historically, Other Gross PP&E Adjustments has averaged -$5.5 million across 5 years, with a median of -$8.6 million in 2022.
  • Biggest five-year swings in Other Gross PP&E Adjustments: soared 88.74% in 2021 and later fell 29.92% in 2024.
  • Tracing VNDA's Other Gross PP&E Adjustments over 5 years: stood at $3.2 million in 2021, then soared by 42.7% to $4.6 million in 2022, then surged by 33.17% to $6.1 million in 2023, then surged by 43.19% to $8.8 million in 2024, then dropped by 14.1% to $7.5 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for VNDA at $7.5 million in Q4 2025, -$6.1 million in Q3 2025, and -$8.3 million in Q2 2025.